G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8
Abdul Qader Sukkurwala,Isabelle Martins,Isabelle Martins,Isabelle Martins,Wang Y,Wang Y,Wang Y,Frédéric Schlemmer,Frédéric Schlemmer,Frédéric Schlemmer,Christoph Ruckenstuhl,Michael Durchschlag,Mickaël Michaud,Mickaël Michaud,Mickaël Michaud,Laura Senovilla,Laura Senovilla,Laura Senovilla,Antonella Sistigu,Antonella Sistigu,Antonella Sistigu,Yuting Ma,Yuting Ma,Yuting Ma,Erika Vacchelli,Erika Vacchelli,Erika Vacchelli,E Sulpice,Xavier Gidrol,L Zitvogel,Frank Madeo,Lorenzo Galluzzi,Lorenzo Galluzzi,Oliver Kepp,Oliver Kepp,Oliver Kepp,Guido Kroemer +36 more
TL;DR: It is shown that pheromones can act as physiological inducers of CRT Exposure in yeast cells, thereby facilitating the formation of mating conjugates, and that a large-spectrum inhibitor of G protein-coupled receptors prevents CRT exposure in human cancer cells exposed to MTX.
Journal ArticleDOI
Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.
Yungan Tao,Ping Zhang,F Girdler,V. Frascogna,Maria Castedo,Maria Castedo,Jean Bourhis,Jean Bourhis,Guido Kroemer,Guido Kroemer,Guido Kroemer,Eric Deutsch +11 more
TL;DR: In this paper, the effects of the bona fide Aurora-B kinase inhibitor AZD1152 on tumor responses to ionizing radiation (IR) were evaluated in vitro and in vivo.
Journal ArticleDOI
Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma.
D. Aguirre,Patricia Boya,Dominique Bellet,S. Faivre,F. Troalen,Jean Bénard,Patrick Saulnier,S. Hopkins-Donaldson,U. Zangemeister-Wittke,Guido Kroemer,Eric Raymond +10 more
TL;DR: In this article, the effects of rapamycin on the mTOR signaling pathway, cell cycle control and apoptosis were studied before and after drug exposure by RT-PCR, and the results indicated that baseline Bcl-2 expression and therapy-induced downexpression of CCND1 and CDK4 may be regarded as molecular markers enabling the prediction and follow-up of the cellular effects on cell cycle.
Journal ArticleDOI
Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus
Lígia C. Gomes-da-Silva,Liwei Zhao,Liwei Zhao,Liwei Zhao,Lucillia Bezu,Lucillia Bezu,Lucillia Bezu,Heng Zhou,Heng Zhou,Heng Zhou,Allan Sauvat,Allan Sauvat,Allan Sauvat,Peng Liu,Peng Liu,Peng Liu,Sylvère Durand,Sylvère Durand,Marion Leduc,Marion Leduc,Marion Leduc,Sylvie Souquere,Sylvie Souquere,Friedemann Loos,Friedemann Loos,Friedemann Loos,Laura Mondragón,Laura Mondragón,Laura Mondragón,Baldur Sveinbjørnsson,Øystein Rekdal,Gaelle Boncompain,Franck Perez,Luis G. Arnaut,Oliver Kepp,Oliver Kepp,Oliver Kepp,Guido Kroemer +37 more
TL;DR: Results point to the capacity of redaporfin to kill tumor cells via destroying ER/GA function through the inhibition of protein secretion by PDT‐treated cancer cells.
Journal ArticleDOI
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
Erika Vacchelli,Fernando Aranda,Alexander M.M. Eggermont,Jérôme Galon,Catherine Sautès-Fridman,Laurence Zitvogel,Guido Kroemer,Lorenzo Galluzzi +7 more
TL;DR: Clinical findings that have been published during the last 13 months as well as clinical trials that have be launched in the same period to investigate the therapeutic profile of hitherto investigational tumor-targeting mAbs are discussed.